Stocklytics Platform
Asset logo for symbol SPRY
Silverback Therapeutics
SPRY49
$14.00arrow_drop_up4.55%$0.60
Asset logo for symbol SPRY
SPRY49

$14.00

arrow_drop_up4.55%

Performance History

Chart placeholder
Key Stats
Open$13.61
Prev. Close$13.79
EPS-0.50
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range13.16
13.99
52 Week Range3.35
19.18
Ratios
Revenue-
EBITDA Margin %-
EPS-0.50

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Silverback Therapeutics (SPRY)

ARS Pharmaceuticals, Inc., also known as SPRY, is a pharmaceutical company that specializes in the development and commercialization of novel therapies for respiratory diseases. The company focuses on creating innovative treatments to address unmet medical needs and improve the quality of life for patients. SPRY has a strong track record in bringing new drugs to market and has a robust pipeline of potential therapies in various stages of development.
As of the most recent trading day, SPRY had a stock price of $X, with a market capitalization of $X. The stock has shown resilience over the past year, with a 52-week range of $X to $X. This indicates that SPRY has managed to navigate through market fluctuations and maintain a steady performance. The day's trading volume for SPRY was X, highlighting the interest and activity surrounding the stock.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
Headquarters
San Diego
Employees
29
Exchange
NASDAQ
add Silverback Therapeutics to watchlist

Keep an eye on Silverback Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the market capitalization of Silverback Therapeutics (SPRY)?

Silverback Therapeutics (SPRY) has a market capitalization of $1.36B. The average daily trading volume is 13.75, indicating the stock's liquidity and investor engagement.
help

What is Silverback Therapeutics 's (SPRY) price per share?

The current price per share for Silverback Therapeutics (SPRY) is $14. The stock has seen a price change of $0.61 recently, indicating a 4.56% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Silverback Therapeutics (SPRY)?

For Silverback Therapeutics (SPRY), the 52-week high is $19.19, which is 37.06% from the current price. The 52-week low is $3.35, the current price is 317.91% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Silverback Therapeutics (SPRY) a growth stock?

Silverback Therapeutics (SPRY) has shown an average price growth of -6.03% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Silverback Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Silverback Therapeutics (SPRY) stock price performance year to date (YTD)?

As of the latest data, Silverback Therapeutics (SPRY) has a year-to-date price change of 150.9%. Over the past month, the stock has experienced a price change of -16.27%. Over the last three months, the change has been 4.48%. Over the past six months, the figure is 58.55%.
help

Is Silverback Therapeutics (SPRY) a profitable company?

Silverback Therapeutics (SPRY) has a net income of -$54.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.05K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$67.52M. Furthermore, the EBITDA is -$56.67M.

News

The Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation
PHYSICIAN-PATIENT ALLIANCE FOR HEALTH & SAFETY
PATIENT SAFETY
HEALTHCARE INNOVATION
BOARD OF ADVISORS
Nov 6, 2024

The Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation

ARS Pharmaceuticals, Inc. is on the Move, Here's Why the Trend Could be Sustainable
ARS PHARMACEUTICALS
SPRY
PRICE TREND
FUNDAMENTALS
EARNINGS ESTIMATE REVISIONS
Oct 14, 2024

ARS Pharmaceuticals, Inc. is on the Move, Here's Why the Trend Could be Sustainable

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
ARS PHARMACEUTICALS
WEDBUSH PACGROW HEALTHCARE CONFERENCE
INTRANASAL EPINEPHRINE
SEVERE ALLERGIC REACTIONS
ANAPHYLAXIS
Aug 7, 2024

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
Jun 28, 2024

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
HEALTH
LICENSING AGREEMENTS
Apr 30, 2024

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
Apr 3, 2024

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

Take Your Investments to a Whole New Level